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The best treatment for children with acute lymphoblastic leuke-
mia (ALL) in second complete remission (CR) after an early bone
marrow (BM) relapse (#36 months from diagnosis) is an HLA-
matched sibling transplant. However, only a third of children who
would benefit from this treatment have a matched sibling. Trans-
plantation using a suitably matched unrelated donor is controversial
given the risks of treatment-related mortality (TRM) is higher and
may have an adverse effect on leukemia-free survival (LFS). To ad-
dress this question, we compared transplant-outcomes in 92 recipi-
ents of HLA-matched sibling BM transplantations and 229
recipients of unrelated donor transplantations (n5 156, BM graft
and n5 73, cord blood [CB]). Patients were aged 1-15 years, had
early relapse and were in second CR at transplantation. Transplants
occurred from 1997 to 2005, and the median follow up of surviving
patients was 5 years. CB recipients were younger (median 6 years)
compared to unrelated BM (7 years) and matched sibling BM recip-
ients (8 years). All patients received total body irradiation containing
conditioning regimens and calcinuerin inhibitor containing graft-
versus-host disease (GVHD) prophylaxis. Forty-nine percent of un-
related donor BM recipients were matched at HLA-A, -B, -C, and
-DRB1, and 14% of CB matched at HLA-A, -B, and -DRB1, the
standard for this graft. We first examined TRM, leukemia relapse
and LFS after unrelated donor BM and CB transplantation and
found no differences. Therefore, for all subsequent analyses, all un-
related donor transplant recipients were grouped together. In multi-
variate analysis, we observed no differences in risks of
relapse(RR5 0.9, p5 0.092) or treatment failure [death or relapse,
inverse of LFS] (RR5 1.2, p5 0.291) after HLA-matched sibling
and unrelated donor transplant. Compared to HLA-matched sibling
transplant, grade 2-4 acute GVHD (RR 2.8, p\0.001), chronic
GVHD (RR 4.2, p\0.001) and TRM (RR5 1.9, p5 0.045), were
higher after unrelated donor transplants. The table below shows
the probabilities (95% confidence interval [CI]) of acute GVHD at
day-100, chronic GVHD, TRM, relapse and LFS at 3-years.
When transplantation is the optimal treatment option, transplanta-
tion of BM from a suitably matched unrelated donor or CB unit
with an adequate cell dose is an acceptable alternative for children
without an HLA-matched sibling.
Transplant TypeOutcome HLA-matched sibling Unrelated donorAcute GVHD* 22% (95% CI 15-31) 51% (95% CI 45-57)
Chronic GVHD* 10% (95% CI 5-17) 30 % (95% CI 25-36)
TRM* 13% (95% CI 7-20) 26% (95% CI 20-31)
Relapse 37% (95% CI 27-47) 31% (95% CI 25-37)
LFS 50% (95% CI 40-60) 43% (95% CI 37-49)* indicates statistical significance.295
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In a retrospective study, we evaluated the cost and cost-effective-
ness of allogeneic peripheral blood stem cell transplantation
(PBSCT) (n5 30) compared with bone marrow transplantation
(BMT) (n5 110) in children with acute leukemia at 1 year of follow
up. Treatment success was defined as disease free survival at one year
post transplant. The inpatient days (42.9 d for PBSCT; 36.8 d for
BMT) and costs from day of admission to transplantation to day of
discharge ($282,577 for PBSCT; $208,987 for BMT) were not sig-
nificantly different between these two groups during the initial hos-
pitalization for transplantation. From the initial hospitalization to
100 days post transplant, the PBSCT group cost was $147,906 com-
pared to $103,428 for the BMT group (P5NS). From 100 days post
transplant to 1 year, PBSCT cost was $106,683 compared to
$124,578 for BMT (P5NS). For standard risk disease patients the
treatment success rate was 57.1% for PBSCT patients and 80.3%
for recipients of BMT (P5NS). The average total cost per treat-
ment success at 1 year in the standard risk disease group was
$512,294 for the PBSCT group and $352,885 for the BMT group
(P5NS). For patients with high risk disease, the treatment success
rate was 18.8% for PBSCT patients and 23.5% for BMT (P5NS).
The cumulative average cost for patients in the BMT group was
$457,078 compared to $377,316 for PBSCT (P5NS). Point esti-
mates of the incremental cost-effectiveness ratio (ICER) indicate
that allogeneic transplantation of bone marrow grafts is dominant
over PBSCT for its lower costs and higher effectiveness in patients
with standard risk disease (ICER5 -$687,108; 95% CI5 $2.4 mil-
lion to dominated). For patients with high risk disease, BMT was
more effective and more costly and the ICER was $1.69 million
(95% CI5 $29.7 million to dominated) per additional treatment
success. The comparative economic evaluation provides support
for BMT for standard risk patients, but the large degree of uncer-
tainty precludes definite support for either treatment option in pa-
tients with high risk disease.296
ALDEHYDE DEHYDROGENASE CELL DOSING PREDICTS THE DOMINAT-
ING CORD IN DOUBLE CORD BLOOD TRANSPLANTATION
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Use of two cord blood units (CBU) for transplantation of a single
patient has increased access to cord blood transplantation (CBT) for
patients previously limited by the cell dose from a single CBU. With
two CBUs, cell dose can be increased above critical thresholds but,
typically, one CBU confers durable engraftment. To date, it has
not been possible to predict which CBU will engraft. We are inter-
ested in hematopoietic stem cells expressing high levels of aldehyde
dehydrogenase [ALDHbr], an intracellular enzyme enumerated by
rapid flow cytometric assay. We have shown that ALDHbr dose cor-
relates with CBU potency. We hypothesize that the CBU delivering
the highest ALDHbr dose establishes durable engraftment after dou-
ble CBT (dCBT).
Methods: From 9/07-3/09, 27 consecutive adult and pediatric pa-
tients underwent dCBT for malignancies. Most (n5 24) received
myeloablative conditioning. We prospectively measured the
ALDHbr dose from both CBUs at time of thaw (Aldecount , Alda-
gen, Inc). Patient and graft characteristics were correlated with out-
comes. Engraftment was defined as the first of 3 days with anS267
